catalytic organometallic anticancer complexes有机金属抗癌配合物催化.pdfVIP

Catalytic organometallic anticancer complexes † ‡ ‡ † ‡§ Sarah J. Dougan , Abraha Habtemariam , Sarah E. McHale , Simon Parsons , and Peter J. Sadler †School of Chemistry, University of Edinburgh, West Mains Road, Edinburgh EH9 3JJ, United Kingdom; and ‡Department of Chemistry, University of Warwick, Gibbet Hill Road, Coventry CV4 7AL, United Kingdom Edited by Jack Halpern, University of Chicago, Chicago, IL, and approved May 23, 2008 (received for review January 4, 2008) Organometallic complexes offer chemistry that is not accessible to effects on cytotoxicity, which is also influenced by the nature of purely organic molecules and, hence, potentially new mechanisms the arene ligand (11). In this series of diamine complexes, of drug action. We show here that the presence of both an iodido changing the monodentate ligand X from chloride to iodide has ligand and a -donor/-acceptor phenylazopyridine ligand confers little effect on activity; both are good leaving groups (12). This remarkable inertness toward ligand substitution on the half-sand- contrasts dramatically with the chlorido and iodido rutheni- wich ‘‘piano-stool’’ ruthenium arene complexes [( 6 -arene)Ru(az- um(II) arene complexes reported here, which contain -donor/ py)I] (where arene p-cymene or biphenyl, and azpy N,N- -acceptor 2-phenylazopyridines as N ,N -chelating (YZ) ligands. dimethylphenyl- or hydroxyphenyl-azopyridine) in aqueous Unlike their en analogues, these complexes exhibit different solution. Surprisingly, despite this inertness, these complexes are solution chemistry,